Shirley Wang

Brigham and Women's Hospital and Harvard Medical School
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (29)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Objectives To develop and validate machine learning (ML) models that predict probable cause of death (CoD) using structured electronic health record (EHR) data, unstructured clinical notes, and publicly available sources. Materials and Methods This multi-institutional retrospective study was conducted across Vanderbilt University Medical Center (VUMC) and Massachusetts General Brigham (MGB), including deceased patients with encounters between October 1, 2015, and January 1, 2021, and confirmed death records. The cohort included 13 708 patients from VUMC and 34 839 from MGB.The primary outcome was underlying CoD categorized into the top 15 National Center for Health Statistics rankable causes, with others grouped as “Other.” Performance was assessed using weighted area under the receiver operating characteristic curve (AUC) and F-measure. Results The XGBoost model using structured EHR data alone achieved weighted AUCs of 0.86 (95% CI, 0.84-0.88) at VUMC and 0.80 (95% CI, 0.79-0.80) at MGB. Adding unstructured notes improved performance, with weighted AUCs of 0.90 (95% CI, 0.88-0.93) at VUMC and 0.92 (95% CI, 0.91-0.92) at MGB. Adding publicly available data did not further improve performance. Cross-institutional validation revealed significant performance degradation. Discussion Models integrating structured and unstructured EHR data show strong within-institution performance but limited generalizability across healthcare systems, highlighting challenges related to institutional data heterogeneity. Conclusions Machine learning models combining structured and unstructured EHR data accurately predict CoD within institutions but perform poorly across sites. Health-care institutions may benefit from adopting robust processes for locally tailored models, and future research should focus on enhancing model generalizability while addressing unique institutional data environments.

Year:

2026

Year:

2026

Objectives Real-world evidence (RWE) increasingly informs clinical decisions, yet manual adjustment for confounding limits scalability. Data-adaptive (DA) algorithms for high-dimensional proxy adjustment show promise but have not been systematically compared to investigator-specified (IS) approaches across diverse treatment scenarios. We evaluated whether DA strategies perform comparably to manually curated IS models using claims-based emulations of 15 randomized trials from the RCT-DUPLICATE initiative. Materials and Methods We identified new-user cohorts for 15 trial emulations in Optum’s de-identified Clinformatics Data Mart Database (2004-2023). Treatment effects were estimated using 3 adjustment strategies: (1) IS models with manually tailored covariates; (2) full-DA strategies using empirical features from semiautomated pipelines; and (3) hybrid-DA models incorporating both empirical and investigator-defined covariates. Agreement with RCT benchmarks was assessed via binary metrics and difference-in-differences. Results Outcome-adaptive LASSO achieved better RWE-RCT agreement than IS adjustment in 73% of full-DA and 87% of hybrid-DA emulations. Other DA methods considering feature associations with both treatment and outcome performed similarly well, while models tuned solely for treatment prediction performed poorly. Performance of IS vs DA strategies differed across emulated trials. Discussion Top DA algorithms matched manual IS models on average, but impact varied by emulation. Case studies illustrate the continued importance of subject-matter knowledge, particularly for complex treatment strategies. Conclusion Data-adaptive algorithms show promise for scalable confounding adjustment in large-scale evidence systems and as augmentation tools for investigator-specified designs. Hybrid strategies combining algorithmic methods with investigator expertise offer the most reliable approach for individual causal questions.

Year:

2026

Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on indirect evidence from heterogeneous trial populations, leaving optimal treatment choices uncertain. Here we conducted five cohort studies to assess the effectiveness of tirzepatide and semaglutide in patients with elevated cardiovascular risk, including obesity and type 2 diabetes, enrolled in insurance programs in the USA between 2018 and 2025. First, we emulated two cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SURPASS-CVOT (tirzepatide versus dulaglutide), to benchmark and critically evaluate our design, data and analytic framework. Second, we assessed each drug in expanded populations reflective of patients routinely seen in clinical practice. Third, we directly compared tirzepatide versus semaglutide. Baseline confounders were balanced using propensity score matching. For the primary composite endpoint of myocardial infarction, stroke or all-cause mortality, benchmarking identified high agreement between the reference trials and their emulations for all individual endpoints except for all-cause mortality in SUSTAIN-6, informing subsequent analyses. In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01). In the head-to-head comparison of tirzepatide versus semaglutide, the hazard ratio was 1.06 (95% CI 0.95 to 1.18). These findings support a comparable cardiovascular benefit of tirzepatide and semaglutide in clinical practice and demonstrate how rigorously designed real-world evidence can complement randomized clinical trials. ClinicalTrials.gov registration: NCT06659744 , NCT07088718 , NCT07096063 .

Year:

2026

Claims‐based analyses can suffer from residual and unmeasured confounding due to factors that are poorly captured in claims. Some of these factors may be measured in other data sources, such as in structured fields of electronic health records (EHR), for example, laboratory test results, or in free‐text physician notes. We conducted a proof‐of‐principle study to demonstrate a process for evaluating the potential risk of confounding—factors poorly captured in claims data but measurable in the EHR as part of drug safety surveillance activities. In future practical applications, this approach could be used along with other sensitivity analyses to evaluate potential residual confounding (e.g., E ‐values, negative controls). We used claims‐EHR linked data from the Mass General Brigham site of the US Food and Drug Administration's (FDA) Sentinel Real World Evidence Data Enterprise. We extracted a cohort that was previously used in a prototypical Sentinel claims‐based query that compared initiators of sacubitril‐valsartan vs. angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers on the risk of angioedema. In this cohort, we used EHR data to characterize angioedema risk factors poorly captured in claims and observed that claims‐based proxies balanced most risk factors that were measurable only in EHR data. While quantitative bias analysis methods can be used to adjust for residual confounding using external information on magnitude and direction of bias, this was deemed unnecessary for this example due to the observed balance achieved on risk factors for angioedema measured in the EHR. A robust linked EHR‐claims data infrastructure is crucial for routine application of these methods to evaluate and mitigate residual confounding in drug safety surveillance studies.

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (17)

Massimiliano Russo

Harvard University

UNITED STATES
View details

Daniel Prieto-Alhambra

Professor (part-time)

Erasmus MC

NETHERLANDS
View details

Jennifer L. Lund

University of North Carolina at Chapel Hill

UNITED STATES
View details

Kevin Wing

Senior Lecturer in Epidemiology

University of Glasgow

UNITED KINGDOM
View details

Judith Maro

-

UNITED STATES
View details

Joshua Smith

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Jie Yang

Harvard University

UNITED STATES
View details

Melissa McPheeters

Research Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Katie Harron

Associate Professor

University College London

UNITED KINGDOM
View details

Kathryn Gray

Associate Professor

Washington University School of Medicine

UNITED STATES
View details

Mohammed Al-Garadi

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Sebastian Schneeweiss

Harvard University

UNITED STATES
View details

George (Shao Qian) Tan

Monash University Malaysia.

AUSTRALIA
View details

Jenni Ilomaki

Senior Lecturer

-

AUSTRALIA
View details

Kristian Filion

Associate Professor

McGill University

CANADA
View details

Sonia Hernandez Diaz

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Stuart Nicholls

Assistant Professor

University of Ottawa

CANADA
View details